Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical-technology.com image

News from pharmaceutical-technology.com

Ground News rates Pharmaceutical-technology.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical-technology.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical-technology.com

Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical-technology.com News

Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion deal — REUTERS / ixx511

Tylenol · United States

Kimberly-Clark buying Tylenol maker Kenvue in $48.7 billion deal

61% Center coverage: 188 sources

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

FDA · United States

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

58% Center coverage: 24 sources

(MedPage Today) -- The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday. A pair of pyrimidine nucleosides, the doxecitine...See the Story

Lilly to build $3 billion Dutch plant to boost weight-loss pill production — REUTERS / pwu404

Eli Lilly · Netherlands

Lilly to build $3 billion Dutch plant to boost weight-loss pill production

42% Center coverage: 12 sources

Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched experimental weight-loss pill, orforglipron, and other oral medicines.See the Story

Breaking News Topics Related to Pharmaceutical-technology.com